Journal
JOURNAL OF PHYSIOLOGY-LONDON
Volume 596, Issue 15, Pages 2985-2989Publisher
WILEY
DOI: 10.1113/JP274350
Keywords
-
Categories
Funding
- ERACoSysMed [15/ERA-CSM/3267]
- Science Foundation Ireland [11/PI/1005]
- Science Foundation Ireland (SFI) [11/PI/1005, 15/ERA-CSM/3267] Funding Source: Science Foundation Ireland (SFI)
Ask authors/readers for more resources
Inflammatory bowel disease (IBD) is a common chronic intestinal disorder characterised by a loss of epithelial barrier function leading to the unregulated movement of luminal antigenic material into mucosal tissue with resultant inflammation. In IBD, multiple components of the inflammatory response lead to tissue hypoxia. Mucosal hypoxia leads to the inactivation of prolyl hydroxylase domain-containing (PHD) enzymes, which in turn leads to the stabilisation of the hypoxia-inducible factor (HIF), which induces the expression of barrier protective genes. Furthermore, pharmacological hydroxylase inhibition has been shown to be protective in colitis, at least in part through enhancing intestinal epithelial barrier function through HIF-1-dependent barrier-protective gene expression. Therefore, targeting hypoxia-sensitive pathways represents a new and promising therapeutic approach in IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available